Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGEN NASDAQ:ATHA NASDAQ:DBVT NASDAQ:DTIL NASDAQ:JNCE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGENAgenus$4.38-3.7%$5.02$1.38▼$7.34$144.98M1.44386,281 shs609,155 shsATHAAthira Pharma$3.87+1.0%$3.96$2.20▼$8.26$15.10M3.0122,113 shs32,497 shsDBVTDBV Technologies$9.50-0.9%$9.62$2.20▼$12.78$262.65M-0.3631,166 shs7,870 shsDTILPrecision BioSciences$4.78-2.6%$4.81$3.61▼$9.81$57.87M1.6178,241 shs73,403 shsJNCEJounce Therapeutics$1.88$1.89$0.58▼$5.87$98.94M0.752.46 million shs169,314 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGENAgenus-3.74%-2.23%-2.88%-8.37%-27.60%ATHAAthira Pharma-4.80%+7.50%-2.89%+27.72%-16.41%DBVTDBV Technologies-0.94%-3.75%-3.80%+1.06%+174.96%DTILPrecision BioSciences-2.65%+3.69%+2.58%-0.21%-50.21%JNCEJounce Therapeutics0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGENAgenus$4.38-3.7%$5.02$1.38▼$7.34$144.98M1.44386,281 shs609,155 shsATHAAthira Pharma$3.87+1.0%$3.96$2.20▼$8.26$15.10M3.0122,113 shs32,497 shsDBVTDBV Technologies$9.50-0.9%$9.62$2.20▼$12.78$262.65M-0.3631,166 shs7,870 shsDTILPrecision BioSciences$4.78-2.6%$4.81$3.61▼$9.81$57.87M1.6178,241 shs73,403 shsJNCEJounce Therapeutics$1.88$1.89$0.58▼$5.87$98.94M0.752.46 million shs169,314 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGENAgenus-3.74%-2.23%-2.88%-8.37%-27.60%ATHAAthira Pharma-4.80%+7.50%-2.89%+27.72%-16.41%DBVTDBV Technologies-0.94%-3.75%-3.80%+1.06%+174.96%DTILPrecision BioSciences-2.65%+3.69%+2.58%-0.21%-50.21%JNCEJounce Therapeutics0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGENAgenus 2.50Moderate Buy$14.50231.05% UpsideATHAAthira Pharma 0.00N/A$4.003.36% UpsideDBVTDBV Technologies 2.80Moderate Buy$14.7555.26% UpsideDTILPrecision BioSciences 3.00Buy$47.00883.26% UpsideJNCEJounce Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest DTIL, AGEN, ATHA, DBVT, and JNCE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/19/2025ATHAAthira PharmaMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$4.009/10/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.008/28/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.008/12/2025AGENAgenusZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold6/26/2025DBVTDBV TechnologiesLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/26/2025DBVTDBV TechnologiesJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$21.00(Data available from 9/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGENAgenus$103.46M1.35N/AN/A($13.06) per share-0.34ATHAAthira PharmaN/AN/AN/AN/A$11.60 per shareN/ADBVTDBV Technologies$4.15M62.72N/AN/A$1.42 per share6.69DTILPrecision BioSciences$68.70M0.82N/AN/A$6.87 per share0.70JNCEJounce Therapeutics$82M1.21N/AN/A$3.54 per share0.53Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGENAgenus-$227.21M-$7.15N/AN/AN/A-167.52%N/A-81.04%11/11/2025 (Estimated)ATHAAthira Pharma-$96.94M-$15.50N/AN/AN/AN/A-139.40%-106.84%11/6/2025 (Estimated)DBVTDBV Technologies-$113.92M-$4.77N/AN/AN/A-3,220.49%-287.15%-138.83%11/5/2025 (Estimated)DTILPrecision BioSciences$7.17M-$8.81N/AN/AN/A-6,205.79%-176.47%-69.05%11/3/2025 (Estimated)JNCEJounce Therapeutics-$50.92M-$2.56N/AN/AN/AN/A-30.90%-26.31%N/ALatest DTIL, AGEN, ATHA, DBVT, and JNCE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025AGENAgenus-$0.78-$1.00-$0.22-$1.00$49.71 million$25.70 million8/7/2025Q2 2025ATHAAthira Pharma-$1.80-$1.80N/A-$0.18N/AN/A8/7/2025Q2 2025DTILPrecision BioSciences-$0.09-$2.13-$2.04-$2.13$6.27 million$0.02 million7/29/2025Q2 2025DBVTDBV Technologies-$0.21-$1.55-$1.34-$1.55$0.64 million$1.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGENAgenusN/AN/AN/AN/AN/AATHAAthira PharmaN/AN/AN/AN/AN/ADBVTDBV TechnologiesN/AN/AN/AN/AN/ADTILPrecision BioSciencesN/AN/AN/AN/AN/AJNCEJounce TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGENAgenusN/A0.060.06ATHAAthira PharmaN/A10.8110.81DBVTDBV TechnologiesN/A2.452.45DTILPrecision BioSciences0.665.185.18JNCEJounce TherapeuticsN/A8.378.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGENAgenus61.46%ATHAAthira Pharma57.12%DBVTDBV Technologies71.74%DTILPrecision BioSciences37.99%JNCEJounce Therapeutics80.66%Insider OwnershipCompanyInsider OwnershipAGENAgenus5.50%ATHAAthira Pharma22.10%DBVTDBV Technologies1.44%DTILPrecision BioSciences4.50%JNCEJounce Therapeutics6.92%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGENAgenus44031.86 million30.11 millionOptionableATHAAthira Pharma403.94 million3.07 millionOptionableDBVTDBV Technologies8027.40 million27.00 millionOptionableDTILPrecision BioSciences20011.79 million11.26 millionNo DataJNCEJounce Therapeutics13752.63 million48.99 millionOptionableDTIL, AGEN, ATHA, DBVT, and JNCE HeadlinesRecent News About These CompaniesPhilly Nonprofit Jounce Partners Helps Teachers Unlock Their Students’ Full PotentialFebruary 17, 2025 | msn.comTaboola Partners with Jounce Media to Verify Ad Inventory is Free From Made for Advertising (MFA) PropertiesOctober 2, 2024 | markets.businessinsider.comAdLib Media Group and Jounce Media PartnerAugust 14, 2024 | destinationcrm.comDJounce Therapeutics gets grant for monoclonal antibody for treating cancer by binding PD-1April 15, 2024 | pharmaceutical-technology.comPMultimatic Jounce Control Dampers Now Available For Chevy Colorado ZR2April 13, 2024 | gmauthority.comG2024 Jeep Gladiator Mojave Keeps On Truckin'April 8, 2024 | caranddriver.comCSan Diego VC, OrbiMed make competing buyout offers for struggling TheseusNovember 27, 2023 | bizjournals.comJounce Media Designates Yahoo Backstage as the Open Web's Largest MFA-Free Supply SourceSeptember 19, 2023 | tmcnet.comKargo Is Industry’s Only Scaled 100% Premium SSP According To Jounce MediaSeptember 18, 2023 | finance.yahoo.comMediavine Represents the Largest Percentage of DEI-owned Websites, Per Data from Jounce MediaSeptember 5, 2023 | tmcnet.comBoard Member at Jounce Therapeutics Exercises Options Worth $324KMay 5, 2023 | benzinga.comBoard Member at Jounce Therapeutics Exercises Options Worth $172KMay 4, 2023 | benzinga.comJounce Therapeutics Director Acquires 51,400 Shares After Exercising Company Stock OptionsMay 4, 2023 | benzinga.comJounce Therapeutics Board Member Acquires 1,883,269 Shares After Exercising Company Stock OptionsMay 4, 2023 | benzinga.comJounce Therapeutics Announces Closing of Tender OfferMay 3, 2023 | finance.yahoo.comJNCE Jounce Therapeutics, Inc.April 29, 2023 | seekingalpha.comThe past five years for Jounce Therapeutics (NASDAQ:JNCE) investors has not been profitableApril 17, 2023 | finance.yahoo.comWhat is Wall Street's Target Price for Jounce Therapeutics Inc (JNCE) Stock Monday?March 29, 2023 | benzinga.comJNCE STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Jounce Therapeutics, Inc. Is Fair to ShareholdersMarch 27, 2023 | markets.buffalonews.comMBuyout Offer Sends Jounce Jumping 20%March 27, 2023 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 2025With Rate Cuts Ahead, Buffett-Backed Builders Look Like a BuyBy Jordan Chussler | September 4, 2025Constellation Lowers Outlook: Time to Panic on Buffett's Big Bet?By Leo Miller | September 12, 2025CrowdStrike Stock Set for Breakout as Agentic AI Demand SurgesBy Chris Markoch | September 17, 2025DTIL, AGEN, ATHA, DBVT, and JNCE Company DescriptionsAgenus NASDAQ:AGEN$4.38 -0.17 (-3.74%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$4.38 0.00 (0.00%) As of 09/19/2025 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.Athira Pharma NASDAQ:ATHA$3.87 +0.04 (+1.04%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$3.83 -0.04 (-1.03%) As of 09/19/2025 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.DBV Technologies NASDAQ:DBVT$9.58 -0.01 (-0.15%) As of 09/19/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.Precision BioSciences NASDAQ:DTIL$4.78 -0.13 (-2.65%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$4.76 -0.02 (-0.31%) As of 09/19/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.Jounce Therapeutics NASDAQ:JNCEJounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas FedEx Delivers Good News: The Bottom Is in for This Stock Tesla: 2 Reasons to Love Musk's $1B Buy, 1 Reason to Be Bearish Azure Leads While AI Excitement Fuels Microsoft Stock The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Darden Restaurants: A Textbook Buy-the-Dip Opportunity McDonald’s: New All-Time Highs Are Inevitable Workday Rising… To Fresh Record High Stock Prices 3 Reasons Amazon Could Be at an All-Time High by October Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
